• Calpain Inhibition: Mechanistic Leverage for Translational O

  2026-06-11

  This thought-leadership article explores how Calpain Inhibitor II, ALLM empowers translational oncology by targeting calpain and cathepsin pathways. Drawing from recent findings on lncRNA-mediated FAK regulation in triple negative breast cancer, we bridge mechanistic insight with strategic guidance for apoptosis and protease inhibition assays, especially in leukemia and lymphoma research. Practical protocol recommendations and a critical outlook position APExBIO’s solution as a catalyst for innovative cancer research.

• Translational Protease Inhibition: From Mechanism to High-Im

  2026-06-11

  This thought-leadership article illuminates the strategic, mechanistic, and translational landscape of protease inhibition, offering researchers actionable insights and evidence-based guidance. By synthesizing state-of-the-art findings—including advances in HIV-1 protease autoprocessing assays and cross-domain research in cancer and infectious disease—the article positions the DiscoveryProbe™ Protease Inhibitor Library as a uniquely powerful resource. It distinguishes itself from standard product literature by bridging biological rationale, workflow validation, and the competitive context for next-generation translational research.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer Model

  2026-06-10

  This study identifies Serine/Threonine Kinase 33 (STK33) as a direct molecular target of the cardiotonic steroid Bufalin in triple-negative breast cancer (TNBC). The findings clarify Bufalin's mechanism as a selective degrader of STK33, providing a new therapeutic angle for TNBC and advancing precision research strategies.

• Protease Inhibitors Block Light-Induced Stomatal Opening in

  2026-06-10

  Wang et al. (2021) developed a chemical screening approach to identify protease inhibitors that disrupt blue light-induced stomatal opening in Commelina benghalensis. Their findings reveal new regulatory mechanisms in guard cell signaling, with implications for plant physiology and chemical biology.

• FAM83A Regulates Mitochondrial Integrity in White Adipocytes

  2026-06-09

  The reference study uncovers a novel physiological role for FAM83A in maintaining mitochondrial function and promoting white adipocyte differentiation via its interaction with casein kinase 1. Utilizing targeted gene knockdown in vivo and in vitro, the research demonstrates that FAM83A is critical for adipogenesis and metabolic homeostasis, offering new insights for obesity and metabolic disease models.

• Mapping Subcellular RNA-Binding Proteins via Functional Prox

  2026-06-09

  This study introduces APEX-PS, a method combining peroxidase-catalyzed proximity biotinylation with phase separation to map subcellular RNA-binding proteins (RBPs) with high spatial and temporal resolution. The approach reveals novel insights into mitochondrial mRNA retention during stress recovery, offering a valuable blueprint for spatially resolved proteomics.

• Telmisartan: Mechanistic Leverage in Cardiac Hypertrophy Mod

  2026-06-08

  This article provides a thought-leadership perspective on leveraging Telmisartan as an angiotensin II receptor antagonist in translational cardiovascular research. Integrating mechanistic insights from recent discoveries around the RIP3/CaMKII axis and necroptosis in cardiac hypertrophy, it offers strategic guidance for experimental design, discusses the evolving competitive landscape, and positions APExBIO's Telmisartan as a precision tool for dissecting hypertension-driven cardiac remodeling.

• U0126 in Overcoming MEK1/2 Inhibitor Resistance: Mechanisms

  2026-06-08

  Explore how the MEK1/2 inhibitor U0126 enables advanced studies on MAPK/ERK pathway blockade and resistance mechanisms in cancer biology. This article uniquely investigates compensatory signaling and practical strategies for overcoming resistance.

• SAR131675: Selective VEGFR-3 Inhibitor for Lymphangiogenesis

  2026-06-07

  SAR131675 is a highly selective and ATP-competitive VEGFR-3 inhibitor with nanomolar potency and minimal off-target activity. It robustly blocks VEGFR-3 autophosphorylation, inhibits lymphatic endothelial cell survival, and demonstrates significant anti-lymphangiogenic and anti-angiogenic effects in preclinical models.

• N1-Methylpseudouridine: Precision mRNA Modification for Adva

  2026-06-06

  Explore how N1-Methylpseudouridine, a leading modified nucleoside, enables superior mRNA translation enhancement and reduced immunogenicity in complex genetic assays. This article uniquely connects advanced nucleoside chemistry to functional genomics applications.

• SIS3 (Smad3 Inhibitor): Precision Modulation for Early Fibro

  2026-06-05

  Explore how SIS3, a potent Smad3 inhibitor, enables advanced dissection of the TGF-β signaling pathway in early-stage fibrosis and osteoarthritis research. This article offers unique assay insights, translational guidance, and practical protocol considerations beyond conventional applications.

• Probenecid (4-(dipropylsulfamoyl)benzoic acid): Mechanisms a

  2026-06-05

  Probenecid is a validated inhibitor of organic anion transporters, multidrug resistance-associated proteins (MRPs), and pannexin-1 channels. It is widely used for reversing multidrug resistance in leukemia models and confers neuroprotection in cerebral ischemia/reperfusion injury. This article details its mechanisms, evidence base, and workflow parameters for laboratory application.

• Olsalazine Sodium: Mechanistic Insights and Transporter Impa

  2026-06-04

  Explore the unique dual utility of Olsalazine Sodium as a mesalamine dimer in both cancer and xenobiotic transporter research. This article reveals new mechanistic perspectives and practical assay implications, setting it apart from previous reviews.

• AMD-070 Hydrochloride: CXCR4 Antagonist for Advanced Assays

  2026-06-04

  Mavorixafor hydrochloride (AMD-070 hydrochloride) from APExBIO is a potent oral CXCR4 antagonist uniquely positioned for translational and cell-based research. Its high solubility, selectivity, and robust clinical data enable reliable workflows in cell migration, anti-HIV, and hematologic disorder models.

• Protease Inhibitor Cocktail EDTA-Free: Advanced Workflow Gui

  2026-06-03

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO ensures robust protein integrity during extraction, even for phosphorylation-sensitive applications. This in-depth guide details experimental protocols, troubleshooting, and the translational impact of using an EDTA-free formulation in multi-omics and signaling studies.

16071 records 1/1072 page Next 12345 下5页 Last page